Overview

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if eniluracil/5-FU/leucovorin in metastatic breast cancer (MBC) may have efficacy and tolerability advantages over capecitabine monotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Adherex Technologies, Inc.
Treatments:
Capecitabine
Eniluracil
Fluorouracil
Leucovorin